Mark R. Hake

Mark R. Hake

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Moderna Has Ripped Through Analyst Estimates This Year, and Might Not Stop

Moderna has blasted through analysts' earnings this year and might keep doing that. FCF could end up much more than analysts foresee next year, pushing MRNA stock 44% higher to $618 per share.

Sundial Stock Is Still Too High, Even with Its Cash and Acquisitions

Sundial Growers is still too pricey today. SNDL stock is worth just 68 cents, at 10 times sales with its new Spiritleaf acquisition.

AbbVie Is Worth 28% More Based on Impressive Dividends

AbbVie is still cheap despite its gains and has an attractive prospective yield. ABBV stock trades for less than 8x next year's earnings with a prospective 5.3% yield, making it 28.5% undervalued.

Buy Viacom Stock Before Its Price Rises 28%

Many were concerned about the low free cash flow that VIAC stock presented in its latest earnings, but the future still looks bright for it.

A Hero Couldn’t Even Rescue Cloudflare From Overvalued Territory Now

Analysts keep hiking revenue forecasts for Cloudflare, pushing NET stock higher. NET stock is not worth more than its price today, even making some heroic assumptions about its future sales and FCF.